congenital abnormalities . We believe that direct inspection by the surgeon ( in a life-sized model ) could inform [ the surgeon ] prior to the operating room , and prior to finding unforeseen surprises [ when searching for ] where exactly to place the left ventricular assist device . Taking this to the next level , I can foresee that we would print life-sized hearts [ to create ] custom-designed assist devices , and find solutions for patients with congenital heart disease .
I can foresee that we would print life-sized hearts [ to create ] with customdesigned assist devices , and find solutions for patients with congenital heart disease . use the software . Most credit for this paper , I think , goes to Kanwal Farooqi , MD , who is the first author on our paper and a pediatric cardiologist . It can be done , and I think it will become commonplace for these procedures .
Walk us through your review . You cover a variety of different topics on how this might work . I have to start by admitting that , as a regular adult cardiologist , congenital heart disease is not something that I am as intimately familiar with as mechanical circulatory support itself . So in this review ,
Add Corlanor ® to maximally tolerated doses of beta-blockers and help give appropriate patients with heart rate ≥ 70 bpm and stable , symptomatic chronic HF ...
MORE HOME . LESS HOSPITAL .
In your review , you actually go through the ABCs of 3D printing . What does someone have to know in order to just get this idea in mind of coming up with this 3D package ? There is a cost spectrum , and we address this in the article . We were actually asked to do this , which I think was an excellent suggestion by the editors .
We used a relatively cheap printer that only cost $ 5,000 . You can do this with slightly cheaper printers , but [ the cost ] goes up . You can spend hundreds of thousands of dollars to get really beautiful replicas of these hearts ( I should also say that the technology itself isn ’ t detailed or summarized in our article ). If you have the equipment , most people would be able to do this . At this moment , it still requires a person that really knows how to
Learn how you can DO MORE with Corlanor ® to reduce the risk of hospitalization for worsening heart failure ( HF ) 1 CorlanorHCP . com
Indication
Corlanor ® ( ivabradine ) is indicated to reduce the risk of hospitalization for worsening heart failure in patients with stable , symptomatic chronic heart failure with left ventricular ejection fraction ≤ 35 %, who are in sinus rhythm with resting heart rate ≥ 70 beats per minute and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use .
Important Safety Information
Contraindications : Corlanor ® is contraindicated in patients with acute decompensated heart failure , blood pressure < 90 / 50 mmHg , sick sinus syndrome , sinoatrial block , 3 rd degree atrioventricular block ( unless a functioning demand pacemaker is present ), a resting heart rate < 60 bpm prior to treatment , severe hepatic impairment , pacemaker dependence ( heart rate maintained exclusively by the pacemaker ), and concomitant use of strong cytochrome P450 3A4 ( CYP3A4 ) inhibitors .
Fetal Toxicity : Corlanor ® may cause fetal toxicity when administered to a pregnant woman based on embryo-fetal toxicity and cardiac teratogenic effects observed in animal studies . Advise females to use effective contraception when taking Corlanor ® .
Atrial Fibrillation : Corlanor ® increases the risk of atrial fibrillation . The rate of atrial fibrillation in patients treated with Corlanor ® compared to placebo was 5 % vs . 3.9 % per patient-year , respectively . Regularly monitor cardiac rhythm . Discontinue Corlanor ® if atrial fibrillation develops .
Bradycardia and Conduction Disturbances : Bradycardia , sinus arrest and heart block have occurred with Corlanor ® . The rate of bradycardia in patients treated with Corlanor ® compared to placebo was 6 % ( 2.7 % symptomatic ; 3.4 % asymptomatic ) vs . 1.3 % per patient-year , respectively . Risk factors for bradycardia include sinus node dysfunction , conduction defects , ventricular dyssynchrony , and use of other negative chronotropes . Concurrent use of verapamil or diltiazem also increases Corlanor ® exposure , contributes to heart rate lowering , and should be avoided . Avoid use of Corlanor ® in patients with 2 nd degree atrioventricular block unless a functioning demand pacemaker is present .
Adverse Reactions : The most common adverse drug reactions reported at least 1 % more frequently with Corlanor ® than placebo and that occurred in more than 1 % of patients treated with Corlanor ® were bradycardia ( 10 % vs . 2.2 %), hypertension or increased blood pressure ( 8.9 % vs . 7.8 %), atrial fibrillation ( 8.3 % vs . 6.6 %), and luminous phenomena ( phosphenes ) or visual brightness ( 2.8 % vs . 0.5 %).
Please see Brief Summary of full Prescribing Information on adjacent page .
BPM = beats per minute ; HF = heart failure . Reference : 1 . Corlanor ® ( ivabradine ) Prescribing Information , Amgen .
ACC . org / CSWN © 2015 Amgen Inc . All rights reserved . Not for reproduction . USA-998-115485 11-15